The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | CRB-401: is CAR T-cell therapy the future of multiple myeloma treatment?
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the exciting preliminary results of the CRB-401 trial (NCT02658929) investigating the efficacy and safety of anti-BCMA CAR T-cell therapy idecabtagene vicleucel (bb2121) in patients with relapsed/refractory multiple myeloma (MM). Dr Fonesca discusses the trial in terms of response rates and measurable residual disease (MRD) status, and poses that these results are likely to translate well into progression-free and overall survival.
